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ABSTRACT
Introduction. Research into the mechanisms of autoimmune demyelination have highlighted B cells in this process. Therapies 
targeting this population were a recent addition to the multiple sclerosis (MS) drugs portfolio. The SARS-CoV-2 pandemic and 
the risk of severe COVID-19 have challenged the safety of B cell depletion in MS patients.
State of the art. Selective depletion of B cells by monoclonal antibodies as monotherapy in MS has been shown to profoundly 
suppress disease activity among relapsing-remitting MS patients. Furthermore ocrelizumab, a humanised anti-CD20 monoclo-
nal antibody, was the first licensed therapy in primary progressive MS. Based on the concept of the role of B cells in MS, many 
therapeutic approaches are emerging as novel ways to treat autoimmune demyelination. However, during the SARS-CoV-2 
pandemic, a conservative approach toward limiting immune suppression in MS patients has been proposed.
Clinical implications. Emerging evidence does not support the notion of increased susceptibility among MS patients to the 
SARS-CoV-2 infection, or any predisposition toward greater severity of COVID-19. This also does not appear to be the case for MS 
patients undergoing B cell depletion therapies. Thus, any decision to withhold immune suppression in MS patients during the 
SARS-CoV-2 pandemic is probably incorrect. MS therapeutic decision-making should focus on the danger of poorly controlled 
autoimmune demyelination rather than perceived risks from COVID-19.
Future directions. The current pandemic highlights the need to develop more selective and safer methods of immunomodu-
lation in MS. B cells represent several functionally different populations. Further research into the different role of these cells 
during autoimmune demyelination should yield better, safer strategies to control the encephalitogenic process. 
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Introduction
Humanity has faced numerous epidemics over the centu-
ries, and the ability to combat pathogens has been crucial to 
survival. Therefore, infectious diseases are considered as the 
main source of evolutionary pressure for species genotype. So, 
epidemics have resulted in the expansion of alleles providing 
either protection or tolerance to these diseases. Thus heritable 
variations that increased the survival rate against deadly infec-
tious agents in past generations have been naturally selected 
before the hosts had the opportunity to reproduce, and are 
present in the population today, shaping our phenotype [1]. 
Selection pressure may have led to the promotion of alleles 
that are protective against pathogens, but bring with them an 
unfavourable effect on overall organism health. 
  A prime example of such an effect is a selection of human 
population haemoglobin gene variants to prevent severe ma-
laria complications [2]. Although these mutations can cause 
significant health problems such as sickle cell anaemia, their 
hosts benefit from a decrease of the severity of Plasmodium 
infections. 
The idea that selection pressure from an infection can 
shape the genetic landscape of the population, promoting 
alleles that otherwise present deleterious effects, has been 
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used to explain the emergence of autoimmune conditions. It 
is assumed that an inherited predisposition of the immune 
system to react overtly may have been beneficial in past gen-
erations when facing epidemics, but in modern industrialised 
environments it promotes autoreactivity. In such conditions, 
molecular mimicry between a benign pathogen can trigger 
autoimmune diseases [3]. A hygiene hypothesis postulates that 
an increased frequency of infections contributes to a decrease 
in autoimmune and allergic conditions [4]. Conversely, lack 
of infections renders the immune system prone to attack its 
own antigens, resulting in autoaggression. 
One example of the link between infection resistance and 
autoimmunity is a finding that a variant gene encoding the 
cytokine and drug target B-cell activating factor (BAFF) was 
associated with multiple sclerosis (MS) as well as systemic 
lupus erythematosus [5]. The autoimmunity-risk allele was 
associated with upregulated humoural immunity through 
increased levels of soluble BAFF, B lymphocytes, and immu-
noglobulins. Population genetic signatures indicated that this 
autoimmunity variant has been evolutionarily advantageous, 
probably by augmenting resistance to malaria. Thus, a link 
between autoimmunity and infection, as well as an inborn 
programme to combat major epidemics, is being postulated 
as a major aspect of the genetic predisposition toward auto-
immunity including MS.
Autoimmune mechanisms in MS
MS is a chronic inflammatory and autoimmune demyeli-
nating disease manifested by the impairment of nerve conduc-
tion due to the degeneration of neurons and oligodendrocytes 
in the central nervous system (CNS). It has been convincingly 
demonstrated that mechanisms leading to MS development 
depend on an aberrant function of the immune system. A cen-
tral role in this process has been attributed to the disruption of 
self-tolerance and the promotion of autoimmune inflammation 
in the brain and spinal cord [6]. The inflammation is mainly 
driven by autoreactive T and B lymphocytes, directed at target 
antigens of myelin and non-myelin proteins presented in the 
CNS, and mediating tissue injury and its associated myelin 
and neuronal damage [6]. 
  Both pathogenesis and the course of autoimmune de-
myelination are clearly influenced by a complex interaction 
of genetic and environmental factors [7]. With regard to the 
genetic background of MS, the most important risk factor is the 
human leukocyte antigen (HLA) DR15 haplotype. Currently 
more than 200 other genetic variants are known to confer the 
risk to develop the disease, and their role is probably mediat-
ed by immune pathway genes [8, 9]. In addition to a genetic 
susceptibility, a number of epigenetic mechanisms operate in 
MS [10-12]. The fact that most of the genetic predisposition 
for MS is conferred by the DR15 haplotype supports the role 
of T helper cells (Th, CD4+ T cells), since CD4+ T cells recog-
nise antigen in the context of HLA class II molecules [7, 13]. 
  Thus, the central event in the pathogenesis of MS is re-
lated to the induction and uncontrolled action of the Th cells 
that recognise and respond to CNS autoantigens [14]. A set of 
immunodominant peptides have been defined from different 
myelin proteins (e.g. MBP13-32, MBP111-129, MBP146-170, 
PLP139-154, MOG1-20 and MOG35-55) that were shown to 
be able to stimulate a high avidity autoreactive T cells [15]. 
Well over 80% of relapsing-remitting MS (RRMS) patients 
demonstrate an immune response against at least one of these 
peptides [13]. Nevertheless, the exact nature of the antigen 
driving the autoimmunity remains unknown. Furthermore, 
significant crossreactivity and degeneration of the Th cells’ 
antigen-specific responses is a factor complicating disentan-
glement of the primary stimuli promoting the autoimmune 
demyelination [16, 17]. The assumption that CD4+ T cells 
are the main population responsible for initiation of damage 
in CNS during autoaggressive demyelination was confirmed 
by numerous studies carried out with murine models of MS, 
experimental autoimmune encephalomyelitis (EAE) [18]. 
Mice genetically deficient in the presence of CD4+ T cells are 
completely insusceptible to the active induction of disease. 
Furthermore, the main mediator of autoimmune demyelina-
tion is believed to reside within the Th17 subpopulation of Th 
lymphocytes. Th17 cells are characterised by interleukin (IL)-
17A and IL-17F secretion and the expression of transcription 
factors retinoic acid receptor-related orphan receptor alpha 
and gamma [19]. Studies conducted on mice with impaired 
function or the number of Th17 cells showed that these mice 
were significantly resistant to EAE [20, 21]. Autoreactivity to 
myelin peptides involves high avidity myelin-specific T cells, 
which are mostly derived from the memory T cell pool [22]. 
Single-cell Th clones from patients with MS show enhanced 
production of IL-17, granulocyte-macrophage colony-stim-
ulating factor (GM-CSF), or interferon gamma; however, 
in healthy controls, IL-10 dominated [23, 24]. Although 
Th17 cells are considered to be the main population that pro-
motes autoimmune demyelination, it has been demonstrated 
both in mice and humans that not all Th17 cells induce tissue 
inflammation and disease (i.e. are ‘pathogenic’). Non-patho-
genic Th17 cells are important players in the healthy organism, 
e.g. a Th17 population resides within the gut’s immune system 
in a response to changes of the microflora [25]. 
  The complicated picture of Th subpopulations, and the 
existence of both pro and anti-immune fractions, are reasons 
why the translation of the data on the role of Th cells in MS 
pathogenesis for the treatment of this condition has not been 
successful so far. Direct depletions of the CD4+ T cells in 
MS patients have yielded negative clinical results [26, 27]. 
An IL-17 inhibition attempt in MS was not followed [28]. 
Antigen-specific approaches are promising, but require 
a complex set of peptides to encompass a high heterogeneity 
of HLA and antigens [29]. An efficient and selective way of 
tackling pathogenic Th17 cells has yet to be established. To 
date, an alternative approach aimed at the manipulation of 
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another MS-driving immune population, B cells, has been 
demonstrated to be highly efficient in slowing this disease.
Role of B cells in autoimmune 
demyelination and B cell targeting therapies 
in MS
Aberrant B-cell responses in the CNS are well known to 
be prominent in MS. The presence of intrathecally synthesised 
immunoglobulin (Ig) G in the form of oligoclonal bands in 
cerebrospinal fluid (CSF) is a biomarker of the disease included 
in the McDonald diagnostic criteria for MS [30, 31]. Clonally 
related B cells have been identified in the blood and CSF of 
MS patients, suggesting a clonal expansion and diversification 
in the periphery and within the CNS during this condition. 
B cells and plasma cells are present in the meninges in MS 
patients [32]. The meningeal foci can become organised in 
lymphoid follicle-like structures which in patients with MS 
is often associated with a more severe disease course and is 
more prevalent in progressive types of the disease [33]. Large 
subpial, cortical MS lesions are also more prevalent in the 
vicinity of the inflammatory infiltrates in the meninges. Thus, 
B cells are likely to contribute to more advanced or progressive 
forms of the condition. Apart from the abnormal secretion of 
the IgG, B cells are also highly potent antigen-presenting cells, 
thereby providing an important link between them and Th 
cells [34]. It has been demonstrated that memory B cells from 
MS patients stimulate autoreactive T cells with brain-homing 
properties. Furthermore, B cells have been shown to be able 
to co-express a novel CNS autoantigen [29]. Overall, B cells 
represent a crucial population with particular properties to 
present autoantigen to T cells in MS patients, both within CNS 
and in the peripheral immune compartments.
B cells are also an important source of many proinflam-
matory cytokines that are likely to promote autoregressive 
and encephalitogenic reactions [34, 35]. B cells from patients 
with MS show increased expression of the immunostimulatory 
nuclear factor κB after activation via the CD40 molecule [36]. 
IL-15, GM-CSF factor, lymphotoxin-α, and tumour necrosis 
factor (TNF) produced by B cells have been found to contrib-
ute to the activation of proinflammatory Th1 and Th17 cells, 
cytotoxic CD8+ T cells, and myeloid cells [37, 38]. A proin-
flammatory, GM-CSF-expressing B cells subset has been found 
to be increased in frequency and more readily induced in MS 
patients compared to healthy controls [37]. Subsets of B cells, 
termed regulatory B cells (Breg cells), that produce immune 
restricting cytokines e.g. IL-10 and IL-35 have also been re-
ported to be less functional in MS [39].
All this data has fuelled interest into the selective thera-
peutic manipulation of B cells as a therapy for MS (Table 1). 
Typically, disease-modifying treatments (DMTs) in MS are 
classified into two categories: immunomodulators or immu-
nosuppressants. Immunomodulators are medications used to 
help regulate or normalise the immune system. Immunosup-
pressive therapies aim to temporarily or permanently alter 
the body’s immune system. These two words are often used 
synonymously with a distinction that modulation appears less 
severe, whereas suppression is applied for stronger, immune 
Table 1. Main published clinical trials in MS with B cell-directed therapies
Trial name Compound name, 
mode of action




HERMES [41] rituximab,  
anti-CD20
intravenous 2 RRMS 104 positive
OLYMPUS [87] rituximab,  
anti-CD20
intravenous 2/3 PPMS 439 negative
OPERA I+II [42] ocrelizumab, 
anti-CD20 humanised
intravenous 3 RRMS 1656 positive
ORATORIO [47] ocrelizumab, 
anti-CD20 humanised
intravenous 3 PPMS 732 positive
MIRROR [43] ofatumumab 
anti-CD20 fully human
subcutaneous 2 RRMS 232 positive
NCT02738775 [44] ublituximab 
anti-CD20 
glycoengineered chimeric
intravenous 2 RRMS 232 positive





1 RRMS 28 positive (safety)
ATAMS [46] atacicept (TACI-Ig), fusion 
protein (TACI receptor 
and Fc domain  
of human IgG1)
subcutaneous 2 RRMS 255 negative; trial 
prematurely 
terminated
NCT02975349 [50] evobrutinib 
oral BTK inhibitor
oral 2 RRMS 267 positive
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cell-depleting therapies [40]. With regard to the usefulness of 
B cell manipulation in MS, immunosuppressive B‐cell‐deplet-
ing clinical studies have so far been particularly informative. 
A successful phase II trial of rituximab, an anti‐CD20 chimeric 
monoclonal antibody, in MS demonstrated this approach to be 
both feasible and effective [41]. CD20 molecule is expressed 
on cells of the B cells lineage from the pre-B cell to the early 
plasmablast stage, and anti-CD20 depletion is an efficient 
and effective tool to remove most of the B cells. A subsequent 
anti‐CD20 antibodies trials has set out to optimise the efficacy 
and safety of B cell depletion in MS. In order to decrease the 
antibody response against anti‐CD20, a humanised anti‐
CD20 monoclonal antibody, ocrelizumab, was developed and 
tested in two twin phase III trials, OPERA I and OPERA II [42]. 
Patients received intravenous ocrelizumab at a dose of 600 mg 
every 24 weeks, or subcutaneous interferon beta-1a at a dose of 
44 μg three times weekly for 96 weeks. The primary end point 
was the annualised relapse rate, which turned out to be lower 
with ocrelizumab than with interferon beta-1a, both in trial 
I (0.16 vs 0.29), and in trial II (0.16 vs 0.29). The percentage 
of patients with disability progression confirmed at 12 weeks 
was significantly lower with ocrelizumab than with interferon 
beta-1a (9.1% vs 13.6%), as was the percentage of patients 
with disability progression confirmed at 24 weeks (6.9% vs 
10.5%). The mean number of gadolinium-enhancing lesions 
per T1-weighted magnetic resonance scan was 0.02 with 
ocrelizumab versus 0.29 with interferon beta-1a in trial I and 
0.02 versus 0.42 in trial II. Moreover, the efficacy and safety of 
a fully humanised anti‐CD20 antibody, ofatumumab, has been 
evaluated in a phase II MIRROR study in RRMS, which showed 
suppression of new MRI lesion development while an antibody 
response against human anti‐CD20 antibodies was not seen 
in treated patients [43]. Two identical phase 3 clinical trials 
of ofatumumab in RRMS (ASCLEPIOS I+II) are currently in 
progress. Ublituximab is a novel chimeric glycoengineered 
IgG1 that binds a unique epitope on CD20 and demonstrates 
increased binding capacity to CD20. Ublituximab was recently 
tested in a phase-II, 48-week, placebo-controlled study, which 
was designed to assess its optimal dose and infusion time in 
48 patients with relapsing forms of MS [44]. This trial has 
shown also positive results of this type of B cell depletion on 
RRMS course. Two identical phase 3 clinical trials of ofatu-
mumab in RRMS (ULTIMATE) are in progress. Inebilizumab 
is a monoclonal antibody which targets another B cell specific 
surface molecule, CD19 [45]. This antibody eliminates B cells, 
pro-B cells, plasmablasts, and plasma cells and may provide 
more complete and prolonged B cell depletion. A phase 1 clini-
cal trial of inebilizumab in relapsing MS patients demonstrated 
an acceptable safety profile and showed a trend in reductions 
in new/newly enlarging and gadolinium-enhancing lesions 
[45]. Conversely, a clinical study testing another B‐cell‐re-
lated therapy, atacicept, a fusion protein of transmembrane 
activator and CAML interactor (TACI) and Fc fragment of 
IgG, designed to target targets B cells and plasma cells but 
not memory B cells, has been tested in MS [46]. This trial has 
resulted in adverse outcomes. Therefore, a functional heter-
ogeneity must exist among B cells, resulting in their capacity 
to be either pathogenic or protective in MS. In addition to 
the involvement of B cells in the pathogenesis of relapsing-re-
mitting MS, ocrelizumab has been shown to be efficacious in 
primary progressive MS (PPMS). In the phase 3 ORATORIO 
study, PPMS patients received intravenous ocrelizumab 
(600 mg) or a placebo every 24 weeks for at least 120 weeks 
and until a pre-specified number of confirmed disability pro-
gression events had occurred. The primary endpoint was the 
percentage of patients with disability progression confirmed 
at 12 weeks in a time-to-event analysis [47]. The percentage of 
PPMS patients with 12-week confirmed disability progression 
was 32.9% with ocrelizumab, versus 39.3% with the placebo. 
The percentage of patients with 24-week confirmed disability 
progression was 29.6% with ocrelizumab versus 35.7% with 
the placebo. This has been accompanied by a positive effect on 
the performance of the timed 25-feet walking test as well as 
favourable changes in MRI parameters [47]. Ocrelizumab was 
the first drug to be proven to be an effective DMT for PPMS. 
These studies have demonstrated the role of both systemic 
and compartmentalised inflammatory processes in MS patho-
genesis, suggesting that anti‐CD20 therapy may be effective 
in managing progression independent of focal inflammation.
In order to avoid elimination of all B cells, including 
pathogenic and non‐pathogenic B cells, resulting in unse-
lective immunosuppression and having some adverse effects, 
targeted B cell tackling approaches are being tested. Bruton’s 
tyrosine kinase (BTK), a member of the Tec family of kinases, 
transmits signals through a variety of receptors in B cells [48]. 
BTK inhibitors are currently under investigation as immuno-
modulators in several types of autoimmune disease, including 
systemic lupus erythematosus, rheumatoid arthritis, and MS. 
Evobrutinib is a selective, covalent, oral inhibitor of BTK that 
blocks B-cell activation and cytokine release and has been 
shown to inhibit their activation [49]. 
Recently, the results of a phase 2 trial of evobrutinib (at 
a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice 
daily) in relapsing MS patients versus open-label dimethyl 
fumarate (DMF) or placebo as a reference have been published 
[50]. The primary endpoint was the total (cumulative) number 
of gadolinium-enhancing lesions identified on T1-weighted 
magnetic resonance imaging at weeks 12, 16, 20, and 24. Pa-
tients with relapsing MS who received 75 mg of evobrutinib 
once daily had significantly fewer enhancing lesions during 
weeks 12 through to 24 than those who received a placebo. 
There was no significant difference with placebo for either the 
25-mg once-daily or 75-mg twice-daily dose of evobrutinib, 
nor in the annualised relapse rate or disability progression 
at any dose [50]. A phase 2b clinical trial with another BTK 
inhibitor, SAR442168, in relapsing MS patients has been 
recently announced to significantly reduce disease activity 
as measured by MRI [51]. Thus, BTK inhibitors may provide 
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efficient therapeutic intervention in MS, expanding the use 
of B cell-targeted therapies in this condition (Tab. 1). BTK is 
also known to function in myeloid cells and its inhibition was 
demonstrated to inhibit the activation, differentiation, and 
polarisation of proinflammatory M1 macrophages and their 
release of cytokines [52]. Therefore, the therapeutic action 
of BTK inhibitors in MS may extend beyond B cells; further 
research is required to explore the full immunomodulatory 
potential of these compounds.
SARS-CoV-2 infection and B cell responses 
in combatting this infection
Coronaviruses are a diverse group of single-stranded pos-
itive sense RNA viruses with a wide range of vertebrate hosts 
[53]. Four common coronavirus types (alpha, beta, gamma, 
and delta) circulate among vertebrates causing gastroenteritis 
in animals. However, in the past two decades, three highly 
pathogenic human betacoronaviruses have emerged [54]. 
These human epidemics were probably a result of a trans-
mission from zoonotic events. In 2002–03, severe acute 
respiratory syndrome related coronavirus 1 (SARS-CoV-1) 
infected more than 8,000 people worldwide with a fatality 
rate of about 10%, followed by Middle East respiratory syn-
drome-related coronavirus (MERS-CoV), which has infected 
2,500 people with a fatality rate of 36% since 2012 [55]. In De-
cember 2019, health authorities in Wuhan, China, identified 
a series of pneumonia cases caused by a previously unknown 
betacoronavirus. This new pathogen was called severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2), and the 
disease has been termed coronavirus disease 2019 (COV-
ID-19). The transmission of SARS-CoV-2 occurs mainly via 
respiratory droplets, similar to the spread of influenza. The 
estimated basic reproduction number and serial interval are 
2.2 and 5–6 days, respectively, with a doubling in the number 
of infected subjects every three days. Since those first cases 
in Wuhan, SARS-CoV-2 has spread rapidly throughout the 
world; on 11 March, 2020, the World Health Organisation 
declared the coronavirus outbreak a pandemic. The clinical 
spectrum of SARS-CoV-2 ranges from asymptomatic disease 
to mild upper respiratory tract infection symptoms (fever, 
sore throat, cough, and fatigue) to severe pneumonia with 
respiratory failure and death [56]. In most of those affect-
ed, SARS-CoV-2 infection is non-symptomatic or mild. 
Epidemiological data shows that young children, including 
infants who are more susceptible to other infections, have 
milder symptoms and less severe COVID-19. The elderly 
and those with co-morbidities (diabetes, obesity, and car-
diovascular, respiratory, renal, and lung diseases) are most 
susceptible to COVID-19 and more likely to suffer from the 
most severe disease complications [57]. The varying degree 
of the SARS-CoV-2 infection burden results from the fact 
that the host’s response to a virus is generally not uniform, 
and infections can induce several different types of reactions 
[58]. SARS-CoV-2 infection-triggered reactions are distinct 
compared to other highly pathogenic coronaviruses and 
common respiratory viruses. It has been shown recently that 
SARS-CoV-2 induces low levels of type I and III interferons 
juxtaposed to elevated chemokines and high expression of 
IL-6 [56]. This may explain why this infection is particularly 
prone to induce hyperacute responses and may transit from 
flu-like symptoms into multi-organ failure.
Reduced innate antiviral defences, coupled with exuberant 
inflammatory cytokine production, have been proposed as 
drivers towards an unfavourable course of COVID-19. It has 
been observed that patients with severe COVID-19, requiring 
intensive care in hospitals, exhibit higher blood plasma levels 
of proinflammatory cytokines, including IL-6, IL-2R, IL-8, 
granulocyte stimulating factor and TNF [58]. IL-6 levels in 
these patients continue to increase over time and are rela-
tively more elevated in non-survivors than in survivors. Such 
upregulation of proinflammatory cytokines is a feature of 
cytokine storm syndrome (CSS). CSS has been known to be 
induced in SARS-CoV-1 or MERS-CoV infections as well as 
to be associated with an autoimmune rheumatic disease, or 
chimeric antigen receptor–T cell (CAR–T cell) therapy [59]. 
In these cases, uncontrolled inflammation inflicts multi-organ 
damage leading to organ failure, especially of the cardiac, 
hepatic and renal systems. CSS also precipitates alveolar in-
flammation and diffuse alveolar damage impairs the infected 
lungs’ ability to participate in gas exchange, culminating in 
acute respiratory distress syndrome (ARDS) and necessitating 
mechanical ventilation [60]. ARDS and multi-organ failure are 
major causes of fatality during COVID-19. The unpredictable 
course of infection, as well as the risk of triggering a systematic 
response, are the reasons for the high concern when dealing 
with the SARS-CoV-2 pandemic.
We are only just beginning to discover the role of different 
immune populations in the responses to the SARS-CoV-2 in-
fection. To this end, the role of B cells is being particularly 
investigated, mainly to understand the role of antibodies pro-
duction in combatting this virus. Recent reports indicate that 
neutralising antibodies are present in the sera collected from 
convalescent COVID-19 patients [61, 62]. Serological analysis 
revealed that SARS-CoV-2-infected patients develop high titres 
of binding and neutralising antibody responses several days 
after the onset of clinical disease. Circulating B cells responsible 
for the production of these antibodies were not dominated by 
any particular clone, suggesting a wide activation of anti-novel 
coronavirus immunoglobulins production [61]. 
Thus, B cells could be critical in combatting the SARS-
CoV-2 virus. The development of therapeutic interventions 
will benefit from a better understanding of the protective B 
cell responses elicited during infection. However, several B 
cell-independent mechanisms of novel coronavirus clearance 
are also in place e.g. through the activation of CD8+ T cells or 
NK cells and the development of anti-SARS-CoV-2 antibodies 
may not be required for effective recovery from COVID-19 [63].
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Proper B cell function is also very important for the ef-
fective development of long-term immunological protection 
following a vaccination [64]. Development of long-term 
immunological memory relies upon humoural and cellular 
immune responses. Vaccinations aim to stimulate these re-
sponses against pathogens. When stimulated in the presence 
of their target antigen delivered during vaccination, B and T 
cells clonally expand, with some transforming into memory 
cells, able to rapidly proliferate and become effector cells upon 
re-exposure to their target antigen. B cells differentiate into 
plasma cells that generate initially IgM and then IgG antibodies 
specific to the vaccine-delivered antigen.
Many candidate SARS-CoV-2 vaccines of different types 
are rapidly undergoing evaluation in clinical trials. Given the 
key role of B cells in antibody development, any therapy affect-
ing B cell status and function is expected to affect the humoural 
responses to a SARS-CoV-2 vaccine. Further studies are 
warranted to elucidate which B cell factors will be critical for 
the success of future vaccines against novel coronavirus [65].
COVID-19 in MS patients
The immune system provides vital defences against viral 
infections. This has raised concern for people with autoim-
munity, including MS, as to whether their immune system 
is capable of efficient clearing of the novel coronavirus. 
Moreover, a safety issue has been raised concerning the use 
of the immunosuppressive and modulatory treatments used 
in MS in SARS-CoV-2 infection, since immune-compromised 
people could be more vulnerable to infections. Infections are 
a particularly important concern during a higher efficacy 
DMT treatment in MS, as a consequence of their more potent 
immunosuppressive activities [66, 67].
When COVID-19 first emerged, given the paucity of 
knowledge surrounding SARS-CoV-2, a conservative prim-
um non nocere approach was recommended when treating 
MS patients. This included the treatment of MS relapses as 
well as recommendations for DMT including higher efficacy 
drugs. MS patients have been considered as being at risk in 
the context of COVID-19 [68]. The emerging data regarding 
COVID-19 susceptibility in the MS population is fortunately 
reassuring. It does not appear that MS patients are more vul-
nerable to the SARS-CoV-2 infection. A recent multicentre 
study led by the Italian programme for COVID-19 infection in 
multiple sclerosis, including 238 symptomatic patients (57 had 
positive RT-PCR) from 38 centres, reported that nearly all pa-
tients (96%) developed a mild disease [69]. Unfortunately, five 
patients died, all of them with EDSS ≥ 6. A study describing 
the experience of an MS centre in Chile included the results 
of an online questionnaire that included COVID-19-related 
information [70]. With 280 received responses, 14.6% reported 
having flu-like symptoms that might have been suggestive 
of COVID-19 infection. Eventually, only three cases of MS 
patients (1.07%) with confirmed SARS-CoV-2 were reported. 
Although these patients were hospitalised, all three have 
since been discharged home [70]. Another recent question-
naire-based study from Poland presented data on 10 MS pa-
tients who tested positive for SARS-CoV-2 [71]. No significant 
changes in neurological status in the course of primary nervous 
system disease have been noted. 
Overall, there is no evidence that MS patients are more 
prone to the SARS-CoV-2 infection or are at a higher risk 
of developing severe COVID-19. Conversely, probably due 
to a younger age and fewer comorbidities, MS patients are 
actually more likely to experience no symptoms or only mild 
signs of this infection.
A central issue for MS patient care during the SARS-
CoV-2 pandemic is their safety while being treated with 
every type of available DMT. Firstly, it is important to note 
that there is no evidence that either immunomodulated or 
immunosuppressed people are at increased risk of coronavirus 
infections [72]. With the emergence of reassuring data on MS 
patients’ status during the SARS-CoV-2 pandemic, the initial 
primum non nocere recommendations are being revised. It is 
emphasised now that the risks of poorly controlled MS might 
outweigh the perceived risks from COVID-19 [73, 74]. This 
results in the gradual evolution of the recommendations for 
MS treatment during the current pandemic. Therefore, to help 
individual MS patient decisions, it is crucial to consider the 
mechanisms of each DMT action, the impact of the treatments 
on infection-risk, vaccination responses and the mechanisms 
of pathology and immunity to SARS-CoV-2 [73].
Particular concern was initially attributed to those MS 
patients undergoing B cell depleted therapies with regard to 
the risk of an aggressive course of SARS-CoV-2 infection [66]. 
This was based on the notion that patients with a decreased B 
cells number might be more susceptible to COVID-19 com-
plications, since this is an immune population responsible for 
generating neutralising antibodies. Considering the half-life of 
the anti-B cell therapies as well as kinetics of the B cells repop-
ulation, it is evident that both rituximab and ocrelizumab cause 
IgM hypogammaglobulinaemia in some people within a few 
treatment cycles, and this and IgA and IgG hypogammaglob-
ulinaemia increases with repeated infusions, potentially con-
tributing to infection [75]. Therefore, B cell depletion might 
result in increased susceptibility to infection. Fortunately, the 
general risk of infections following B cell depletion therapy 
in MS patients has been already reported. Data from OPERA 
I and II shows that pre-existing adaptive immunity was not 
affected by ocrelizumab treatment [76]. Additionally, in the 
study which evaluated the immune response to vaccines in 
patients with relapsing MS (the VELOCE study), although 
reduced compared to placebo-treated patients, patients treated 
with ocrelizumab were able to mount immune responses to 
vaccines and new antigens [77]. The incidence of severe infec-
tions from ocrelizumab in clinical trials was very low (1.3% 
for relapsing MS and 6.2% for primary progressive MS) [78]. 
Some serious infections occurred, including respiratory viral 
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complications, but their incidence was low in clinical trials and 
extended phases [79]. Clinical trials reported similar incidence 
of infections between rituximab and placebo (69.6% and 68.2% 
vs 65.3% and 71.4% respectively) [80]. The incidence of infec-
tions in open-label prospective studies varies widely, ranging 
from 61.5% to 8%, however infections are generally mild to 
moderate [81]. Rituximab decreases immunoglobulins without 
a clear association with serious infection risk [80]. DMTs-in-
duced B cell inhibition would not influence innate and CD8+ 
T cell responses, which allows SARS-CoV-2 elimination [63, 
75]. Therefore, existing data does not support the notion that 
B cell depletion in MS patients with ocrelizumab would be 
deleterious to the clearance of SARS-CoV-2, nor would prevent 
resistance to this pathogen. In order to directly deal with the 
putative risk of COVID-19, recent publications have already 
directly reported on the fate of MS patients treated with B cell 
depleting therapies and undergoing SARS-CoV-2 infection 
(Tab. 2). Reports have described together 262 MS patients 
with COVID-19 treated with either ocrelizumab (n = 195) 
or rituximab (n = 67). These patients were from Europe, the 
US and Iran. Among reported patients, 46 cases of severe or 
critical COVID have been identified, with five leading to fa-
tality (1.9%). One deceased MS patient has been undergoing 
ocrelizumab treatment, and four were rituximab treated (Tab. 
2). Although these studies are observational and could suffer 
from various shortcomings, they provide direct evidence that 
anti-CD20 did not seem to have an important role in the risk 
of infection by SARS-CoV2. Furthermore, there is no evidence 
presently to suggest a more severe course of COVID-19 in 
ocrelizumab-treated MS patients. Favourable evolution of 
COVID-19 has been observed in anti-CD20 treated MS pa-
tients regardless of the presence or absence of anti-SARS-
CoV-2 antibodies, so resolution of the condition could be 
considered to be independent of humoural immunity [82]. 
These findings seem to support the notion that B cell de-
pletion DMTs should not be halted in MS patients and can 
be reasonably continued despite the current danger of SARS-
CoV-2 infection. Furthermore, emerging data does not support 
an increased risk of severe outcome associated with any DMT 
used in MS, which should reinforce the recommendation of not 
stopping current DMTs and not delaying treatment initiation in 
patients who have higher disease inflammatory activity, risk of re-
lapse, or subsequent disability [83]. Hopefully longer observations 
and larger consortia studies will further reinforce this statement.
Future directions
B cell targeting therapies are the newest addition to the 
portfolio of therapeutic strategies for treating MS. Their suc-
cess has confirmed the role of B cells in MS. B cell depletion 
was also successful in PPMS and ocrelizumab became the 
first licensed drug for this condition. Despite recent major 
advances toward a better understanding of the role of B cells 
in MS, there is still much to be discovered. The development 
of more effective and safer therapies directed at B cells should 
focus on compounds that also target specific plasma cells or 
do not affect Breg, and depends on enhanced understanding 
and further research into B cell biology, as well as a better 
understanding of MS pathogenesis. 
 The safety of cell depletion or immunosuppression has 
been a subject of major concern since the dawn of these ther-
apies. This issue became particularly important in the SARS-
CoV-2 pandemic when global populations are at high risk of 
exposure to a dangerous pathogen. Fortunately, the available 
data suggests strongly that the B cell manipulation approach 
in MS patients can be safe even with exposure to SARS-CoV-2.
A number of additional B cell-targeting monoclonal 
antibodies such as epratuzumab (anti-CD22, a negative 
regulator of BCR-derived activation signals), daratumumab 
(anti-CD38 that depletes plasmablasts and some plasma 
cells), LTbR-IgG (anti-lymphotoxin beta receptor that would 
reduce the formation of ectopic germinal centres), NNC114-
0005 (anti-IL21, an important cytokine for Ab formation), 
otilimab (anti-GM-CSF that blocks pro-inflammatory mye-
loid cell response), belimumab and talabumab (anti-BAFF), 
VAY736 (anti-BAFF receptor), hBCMA-Fc (human BCMA 
fused to IgG1 Fc), and antibodies to co-stimulatory mole-
cules have been developed, primarily for use in haematology 
that could potentially be repurposed toward MS treatment. 
Furthermore, a number of small molecules tackling several 
different components of B cell signalling are also in develop-
ment [84]. With increasing evidence for the safety of B cell 
manipulation, these compounds should address the great 
interest in the further development toward novel therapies of 
MS. Recent data indicates that high-efficacy therapies in MS 
commenced within two years of disease onset are associated 
with less disability after 6–10 years than when commenced 
later in the disease course, and B cell targeting compounds 
are considered high-efficacy approaches [85, 86]. 
Although the SARS-CoV-2 pandemic still poses a major 
threat, it appears that general paradigms of MS DMT selection 
should not be sacrificed. It should be noted that novel corona-
virus clearance can occur via B cell-independent mechanisms 
e.g. through the activation of CD8+ T cells and regardless of 
the presence of anti-SARS-CoV-2 antibodies [63]. Therefore, 
B cell targeting therapies may remain an effective way to treat 
MS without the burden of the increased susceptibility to novel 
coronavirus infection.
Hopefully, the emergence of an effective vaccine for novel 
coronavirus will facilitate eradication of this pathogen. Current 
DMTs in MS are unlikely to inhibit development of the effective 
resistance via vaccination, although anti-B cell therapies may 
reduce its effectiveness [65, 75]. Novel drugs in MS, including 
new approaches to tackle B cell function, should be designed to 
provide more selective and less immunosuppressive compound. 
Finally, SARS-CoV-2 pandemic health data is important and 
must be collected to help prepare against and combat future 
infections in both MS patients and the general population.
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Table 2. Studies reporting COVID-19 in MS patients undergoing B cell-depleting therapies
Study DMT No of treated 
MS patients
MS type COVID-19 symptoms or 
severity
Outcome
Novi et al. [88] ocrelizumab 1 PPMS high fever and severe cough Discharged from hospital to 
home-quarantine




not specified mild in overall in MS group, 
severe course in two 
ocrelizumab-treated patients 
(both relapsing-remitting MS), 
severe course and death in 
one rituximab-treated patient 
(PPMS)
Severe course in two MS 
patients treated with 
ocrelizumab recovered, death 
in one rituximab-treated 
patient (PPMS)
Hughes et al. [89] ocrelizumab 100 relapsing forms (30%) 
progressive forms 
























All cases were relatively 
mild and only one required 
hospital admission but without 
complications
Ghajarzadeh et al. 
[91]
ocrelizumab 1 relapsing-remitting 
MS
low-grade fever and mild 
dyspnoea
recovered during  
home-quarantine
Wurm et al. [92] rituximab 1 progressive MS dry cough, dyspnoea, fatigue, 
headache, and nausea








4 RRMS, 1 PPMS 
1 progressive MS
two asymptomatic, two mild, 
one moderate, one severe
asymptomatic or recovered 
completely
Louapre et al. [93] ocrelizumab 1 SPMS mild inflammatory syndrome At 14 days post-COVID-19 
diagnosis remained 
asymptomatic




not specified nine hospitalised, 25 non-
hospitalised
One rituximab-treated 
RRMS patient deceased; one 
ocrelizumab-treated SPMS 
patient deceased; 24 patients 
recovered
Safavi et al. [95] rituximab 21 not specified not specified all recovered
Suwanwongse and 
Shabarek [96]
ocrelizumab 1 not specified dyspnoea, dry cough, nausea, 
vomiting, watery diarrhoea
discharged on day 5 without 
complications
Conte [97] ocrelizumab 1 not specified upper respiratory symptoms, 
malaise
recovered
Lucchini et al. [98] ocrelizumab 1 relapsing MS fever, productive cough, sore 
throat, nasal congestion
recovered




not specified Two severe (grade 6 out of 7), 
remaining milder course 
One deceased (grade 7 out of 7), 
one severe (grade 6 out of 7), 
remaining milder course
One MS patient deceased 
was rituximab-treated until 
18 months before COVID-19 
onset, otherwise no fatalities in 
anti-CD20 treated MS patients 
Rempe Thornton 
and Harel [99]
ocrelizumab 1 RRMS mild cough, dyspnoea on 
exertion
recovered
Barzegar et al. [100] rituximab 1 confirmed SPMS fever, cough, dyspnoea deceased
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